Literature DB >> 11163654

Development of natural immunity to Neisseria meningitidis.

A J Pollard1, C Frasch.   

Abstract

Although meningococcal disease is rare in industrialized nations, Neisseria meningitidis holds a prominent position amongst pediatric infections because of the dramatic clinical presentation of the disease, high mortality, epidemic potential and the recent disappearance of many other important infectious diseases in developed countries through improvements in public health and vaccination. The precise nature of natural immunity to meningococci remains unknown, although a complex interaction between the organism and nasopharyngeal mucosal barrier, innate immune mechanisms and acquired immunity is involved. Study of the mechanisms of natural immunity may provide the key to development of vaccines that can reduce the burden of disease in early childhood.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163654     DOI: 10.1016/s0264-410x(00)00333-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  The oligosaccharide of gonococcal lipooligosaccharide contains several epitopes that are recognized by human antibodies.

Authors:  Ryohei Yamasaki; Uichirou Yabe; Chikako Kataoka; Ushio Takeda; Shunpei Asuka
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

3.  Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Authors:  George K Siberry; Paige L Williams; Jorge Lujan-Zilbermann; Meredith G Warshaw; Stephen A Spector; Michael D Decker; Barbara E Heckman; Emily F Demske; Jennifer S Read; Patrick Jean-Philippe; William Kabat; Sharon Nachman
Journal:  Pediatr Infect Dis J       Date:  2010-05       Impact factor: 2.129

4.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

5.  Expression of plasma cell alloantigen 1 defines layered development of B-1a B-cell subsets with distinct innate-like functions.

Authors:  Hongsheng Wang; Dong-Mi Shin; Sadia Abbasi; Shweta Jain; Alexander L Kovalchuk; Natalie Beaty; Sophia Chen; Ines Gonzalez-Garcia; Herbert C Morse
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-19       Impact factor: 11.205

6.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses.

Authors:  Leanne Peiser; Menno P J De Winther; Katherine Makepeace; Michael Hollinshead; Philip Coull; Joyce Plested; Tatsuhiko Kodama; E Richard Moxon; Siamon Gordon
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis.

Authors:  Terry Guthrie; Simon Y C Wong; Bin Liang; Lisa Hyland; Sam Hou; E Arne Høiby; Svein Rune Andersen
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.

Authors:  Caroline Trotter; Jamie Findlow; Paul Balmer; Ann Holland; Rita Barchha; Nick Hamer; Nick Andrews; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

Review 10.  Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.

Authors:  Elisabeth Kugelberg; Bridget Gollan; Christoph M Tang
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.